Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials

por Chabra, Sanjay, Gill, B. J., Gallo, Gaia, Zhu, Danting, Pitou, Celine, Payne, Christopher D., Accioly, Ana, Puig, Luis
Publicado 2022

Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS)

por Jackson, Kimberley, Chua, Laiyi, Velez de Mendizabal, Nieves, Pitou, Celine, Rodriguez Capriles, Claudia, Paller, Amy S., Lansang, Perla, Seyger, Marieke M. B., Papp, Kim
Publicado 2021

A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

por COHN, ALLEN, LAHN, MICHAEL M., WILLIAMS, KRISTEN E., CLEVERLY, ANN L., PITOU, CELINE, KADAM, SUNIL K., FARMEN, MARK W., DESAIAH, DURISALA, RAJU, ROBERT, CONKLING, PAUL, RICHARDS, DONALD
Publicado 2014

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors

por O'Hara, Mark H., Messersmith, Wells, Kindler, Hedy, Zhang, Wei, Pitou, Celine, Szpurka, Anna M., Wang, Dan, Peng, Sheng-Bin, Vangerow, Burkhard, Khan, Anis A., Koneru, Mythili, Wang-Gillam, Andrea
Publicado 2020

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer

por Goldman, Jonathan W., Rosen, Lee S., Tolcher, Anthony W., Papadopoulos, Kyriakos, Beeram, Muralidhar, Shi, Peipei, Pitou, Celine, Bell, Robert, Kulanthaivel, Palaniappan, Zhang, Xuekui, Fink, Aaron, Chan, Edward M., Shahir, Ashwin, Farrington, Daphne, Patnaik, Amita
Publicado 2017